



## Molecular Partners Nominates Dominik Höchli, M.D., for Election to its Board of Directors

March 25, 2021

- **Pharmaceutical industry expert with extensive knowledge of R&D and commercialization**

**Zurich-Schlieren, Switzerland, March 25, 2021.** [Molecular Partners AG](#) (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the nomination of Dominik Höchli, M.D., to the Company's Board of Directors proposed for election at the 2021 Annual General Meeting on April 21, 2021.

"As Molecular Partners continues to welcome a diverse set of talents to our company, we are pleased to propose Dominik for election to our Board of Directors. With an extensive skill set including global medical affairs, commercialization, and business strategy, we view Dominik as a welcomed addition to our Board, and look forward to his participation in the future success of our Company," said Bill Burns, chairman of the Molecular Partners Board of Directors.

Dominik has 20 years of experience as a marketing and medical affairs executive. Until 2020 he worked at AbbVie as Vice President, Head of Global Medical Affairs and member of the R&D and the Commercial leadership team. He led global product launches for major blockbuster products, including HUMIRA, Maviret, Venetoclax and Skyrizi, and his leadership experience ranges from smaller country organizations and large global functions. He began his corporate career at McKinsey & Co. Dominik is a Swiss national and obtained his medical degree (M.D.) from the University of Bern.

### About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

For more information see [www.molecularpartners.com](http://www.molecularpartners.com) and follow the Company on Twitter at [@MolecularPrtnrs](https://twitter.com/MolecularPrtnrs).

### For further details, please contact:

Investors:

Seth Lewis

[seth.lewis@molecularpartners.com](mailto:seth.lewis@molecularpartners.com)

Tel: +1 781 420 2361

Media:

Shai Biran, Ph.D.

[shai.biran@molecularpartners.com](mailto:shai.biran@molecularpartners.com)

Tel: +1 978 254 6286

Thomas Schneckenburger, European IR & Media

[thomas.schneckenburger@molecularpartners.com](mailto:thomas.schneckenburger@molecularpartners.com)

Tel: +41 79 407 9952

### Forward-looking statements

This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could", and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information.